STOCK TITAN

IDEXX Laboratories (IDXX) director granted 49 deferred stock units

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units of common stock on July 30, 2026 under the company’s Director Deferred Compensation Plan. The grant represents $27,280.22 of deferred cash fees, converted at a closing share price of $558.80 per unit. Each unit equals one IDEXX common share, vests immediately, and will be paid in stock after his board service ends or on other preset dates allowed by the plan.

Positive

  • None.

Negative

  • None.
Insider HOOLEY JOSEPH L
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 49 $558.80 $27K
Holdings After Transaction: Common Stock — 325 shares (Direct)
Footnotes (1)
  1. F1. Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($27,280.22) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.
Deferred stock units acquired 49 units Non-derivative grant to director on 2026-07-30
Deferred cash compensation $27,280.22 Board fees converted into deferred stock units under the Director Deferred Compensation Plan
Reference share price $558.80 per share IDEXX closing common stock price used to calculate number of deferred stock units
Direct holdings after transaction 325 shares Reported direct common stock or equivalent units held by Joseph L. Hooley following the grant
deferred stock units financial
"Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Director Deferred Compensation Plan financial
"acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan")"
Rule 16b-3 regulatory
"acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan in accordance with Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
contingent right financial
"Each deferred stock unit represents a contingent right to receive one share of IDEXX"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did IDEXX (IDXX) director Joseph L. Hooley report in this Form 4?

Joseph L. Hooley reported acquiring 49 deferred stock units of IDEXX common stock as director compensation. These units were granted under the Director Deferred Compensation Plan and represent board fees that were converted into stock-based units instead of being taken in cash.

How many IDEXX (IDXX) deferred stock units did Hooley receive and what was their value?

Hooley received 49 deferred stock units, based on deferred cash compensation of $27,280.22. The number of units was calculated by dividing those fees by the IDEXX closing share price of $558.80 on the deferral date, then rounding to the nearest whole unit.

What is the IDEXX (IDXX) Director Deferred Compensation Plan mentioned in the filing?

The Director Deferred Compensation Plan allows IDEXX directors to defer cash fees into deferred stock units. Each unit represents a contingent right to receive one IDEXX common share, vests immediately upon grant, and is paid in stock after board resignation or on other preset, nondiscretionary dates.

When will Joseph L. Hooley receive IDEXX (IDXX) shares for these deferred stock units?

Each deferred stock unit is payable only in IDEXX common stock after Hooley leaves the board or on other objectively determinable dates chosen under the plan. Although the units vest immediately, actual share delivery is postponed until those specified distribution events occur.

Were Hooley’s IDEXX (IDXX) deferred stock units granted under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not checked, so this acquisition was not identified as occurring under a Rule 10b5-1 trading plan. Instead, it reflects routine director compensation deferred into stock units under the company’s Director Deferred Compensation Plan.

What is Hooley’s IDEXX (IDXX) common stock position after this grant?

After this transaction, Hooley is reported as directly owning 325 shares or equivalent common stock units. This total includes the newly acquired 49 deferred stock units and reflects his overall direct common stock-related position reported for this security class.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HOOLEY JOSEPH L

(Last)(First)(Middle)
ONE IDEXX DRIVE

(Street)
WESTBROOK MAINE 04092

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/30/2026A49(1)A$558.8325D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($27,280.22) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Joseph L. Hooley08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)